No abstract

No abstract

No abstract

In studies of tobramycin an excellent effect was noted against many strains of bacteria of the family Enterobacteriaceae and of Pseudomonas aeruginosa and Staphylococcus derived from clinical sources. When the susceptibility of the strains to tobramycin was compared with susceptibility to other aminoglycoside antibiotics, tobramycin was clearly the most effective antibiotic of this group. Therapy of chronic urinary tract infection with tobramycin resulted in good clinical effects with no (or only slight) adverse reactions. When the parameters of recovery in patients treated with tobramycin were compared with those in other patients who had the same diseases but were treated with gentamicin, tobramycin yielded clinical results that were as good as (and occasionally better than) those produced by gentamicin. Studies of the pharmacokinetics of tobramycin showed a high rate of absorption from the muscles, a high rate of renal excretion, and effective therapeutic concentrations (higher than the minimal inhibitory concentration for the infecting strains) in renal tissue homogenates.

With model experiments we endeavoured to further clinical experience in that infection of patients in a state of immunodepression may be treated more efficiently with bactericidal than with bacteriostatic antibiotic drugs. In cases of lethal infection due to Staphylococcus aureus, we studied the behaviour of animals with intact or immunosuppressed immune systems under bactericidal and bacteriostatic antibiotic therapy. As index we used the mortality rate and the possibility of reculturing the infectious strain. In our experiments we studied the effect of diabetes mellitus and senescence as influencing factors on the course of infection. It was indicated that in diabetic model experiments the effect of bactericidal antibiotic drugs was more advantageous, both in reduced mortality and lower possibility of reculture.